Bay Street News, February, 2024

Three Clinical Stage Programs Targeting PCSK9 and ANGPTL3 Expected in 2024 Announced First Human Proof-of-Concept Data for In Vivo Base […]

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) — Nexxen International Ltd. (AIM/NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, unified […]

MONTREAL, Feb. 27, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company […]

VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) — FIREWEED METALS CORP. (“Fireweed” or the “Company”) (TSXV: FWZ; OTCQB: FWEDF; […]

MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) — Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd., “Norwegian Cruise Line […]

WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology […]

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative […]

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) — AGF Investments Inc. (AGF Investments) announced that effective today it is expanding its […]

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), […]

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) — EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK) (“EnviroGold Global” […]